Cardiovascular

FDA approves drug for rare cholesterol disorder

On Dec. 21, the U.S. Food and Drug Administration approved Juxtapid (lomitapide) to reduce low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares